Ocrelizumab, -, METHYLPREDNISOLONE , DEXAMETHASONE , Ocrevus, -
MN45053
Phase 3 small_molecule active
Quick answer
Ocrelizumab, -, METHYLPREDNISOLONE , DEXAMETHASONE , Ocrevus, - for Neurological Disease is a Phase 3 program (small_molecule) at Roche Registration Limited with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Roche Registration Limited
- Indication
- Neurological Disease
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active